Table 1.

Efficacy of PTX-based chemotherapy for advanced esophageal cancer

Authors	Cases (SC/AC/other)	Chemotherapy	Efficacy
			Total	SC	AC
van der Gaast, et al. [20]	31(NA/NA)	PTX 100–160 mg/m2 iv3h, d1; DDP 60 mg/m2, d1, q2w	55%	53%	60%
Kelsen, et al. [21]	37(27/10)	PTX 200 mg/m2, civ24h, d1; DDP 75 mg/m2, d1, q3w	49%	60%	44%
Polee, et al. [22]	51(16/31/4)	PTX 180 mg/m2, iv3h, d1; DDP 60 mg/m2, d1, q2w	43%	39%	44%
Huang, et al. [23]	30(30/0)	PTX 175 mg/m2, iv3h, d1; DDP 40 mg/ m2, d2, 3, q3w	59%	59%	–
Ilson, et al. [24]	61(31/30)	PTX 175 mg/m2 iv3h, d1; DDP 20 mg/m2 5d; 5-FU 1 g/m2/d, 5d; q3w	48%	50% (CR 20%)	46%(CR 3%)
Lin, et al. [25]	41(41/0)	PTX 35 mg/m2, d1, 4, 8, 11, DDP 20 mg/m2, d2, 5, 9, 12; 5-FU 2 g/m2, q3w	39%	39%	–

Abbreviations: SC squamous cell carcinoma, AC adenocarcinoma, PTX paclitaxel, 5-FU 5-fluorouracil, DDP cisplatin, CR complete response